NASDAQ:GRNV

GreenVision Acquisition Competitors

$10.18
0.00 (0.00 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.17
Now: $10.18
$10.19
50-Day Range
$10.10
MA: $10.17
$10.21
52-Week Range
$9.87
Now: $10.18
$11.55
Volume8,854 shs
Average Volume123,826 shs
Market Capitalization$73.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

GreenVision Acquisition (NASDAQ:GRNV) Vs. FMS, DVA, SHC, PGNY, TVTY, and TLMD

Should you be buying GRNV stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to GreenVision Acquisition, including Fresenius Medical Care AG & Co. KGaA (FMS), DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), Tivity Health (TVTY), and SOC Telemed (TLMD).

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and GreenVision Acquisition (NASDAQ:GRNV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and GreenVision Acquisition's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%
GreenVision AcquisitionN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Fresenius Medical Care AG & Co. KGaA and GreenVision Acquisition, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius Medical Care AG & Co. KGaA19702.35
GreenVision Acquisition0000N/A

Fresenius Medical Care AG & Co. KGaA presently has a consensus target price of $45.00, indicating a potential upside of 19.43%. Given Fresenius Medical Care AG & Co. KGaA's higher probable upside, equities research analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than GreenVision Acquisition.

Institutional and Insider Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Fresenius Medical Care AG & Co. KGaA and GreenVision Acquisition's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.13$1.34 billion$2.5314.89
GreenVision AcquisitionN/AN/AN/AN/AN/A

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than GreenVision Acquisition.

Summary

Fresenius Medical Care AG & Co. KGaA beats GreenVision Acquisition on 6 of the 7 factors compared between the two stocks.

DaVita (NYSE:DVA) and GreenVision Acquisition (NASDAQ:GRNV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares DaVita and GreenVision Acquisition's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DaVita7.32%43.99%5.27%
GreenVision AcquisitionN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for DaVita and GreenVision Acquisition, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DaVita13102.00
GreenVision Acquisition0000N/A

DaVita presently has a consensus target price of $114.60, indicating a potential upside of 5.89%. Given DaVita's higher probable upside, equities research analysts plainly believe DaVita is more favorable than GreenVision Acquisition.

Institutional and Insider Ownership

91.7% of DaVita shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. 1.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares DaVita and GreenVision Acquisition's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$11.39 billion1.04$810.98 million$5.4020.04
GreenVision AcquisitionN/AN/AN/AN/AN/A

DaVita has higher revenue and earnings than GreenVision Acquisition.

Summary

DaVita beats GreenVision Acquisition on 8 of the 8 factors compared between the two stocks.

Sotera Health (NYSE:SHC) and GreenVision Acquisition (NASDAQ:GRNV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Sotera Health and GreenVision Acquisition's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sotera HealthN/AN/AN/A
GreenVision AcquisitionN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Sotera Health and GreenVision Acquisition, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sotera Health001003.00
GreenVision Acquisition0000N/A

Sotera Health presently has a consensus target price of $32.75, indicating a potential upside of 26.30%. Given Sotera Health's higher probable upside, equities research analysts plainly believe Sotera Health is more favorable than GreenVision Acquisition.

Institutional and Insider Ownership

67.7% of GreenVision Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Sotera Health and GreenVision Acquisition's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sotera HealthN/AN/AN/AN/AN/A
GreenVision AcquisitionN/AN/AN/AN/AN/A

Summary

Sotera Health beats GreenVision Acquisition on 2 of the 3 factors compared between the two stocks.

Progyny (NASDAQ:PGNY) and GreenVision Acquisition (NASDAQ:GRNV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Progyny and GreenVision Acquisition's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Progyny1.03%7.43%5.04%
GreenVision AcquisitionN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Progyny and GreenVision Acquisition, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Progyny00603.00
GreenVision Acquisition0000N/A

Progyny presently has a consensus target price of $38.8333, indicating a potential downside of 22.10%. Given Progyny's higher probable upside, equities research analysts plainly believe Progyny is more favorable than GreenVision Acquisition.

Valuation and Earnings

This table compares Progyny and GreenVision Acquisition's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Progyny$229.68 million18.93$-8,570,000.00$0.11453.18
GreenVision AcquisitionN/AN/AN/AN/AN/A

GreenVision Acquisition has lower revenue, but higher earnings than Progyny.

Institutional and Insider Ownership

58.5% of Progyny shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. 33.3% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Progyny beats GreenVision Acquisition on 7 of the 8 factors compared between the two stocks.

Tivity Health (NASDAQ:TVTY) and GreenVision Acquisition (NASDAQ:GRNV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Tivity Health and GreenVision Acquisition's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tivity Health-47.44%128.43%6.11%
GreenVision AcquisitionN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tivity Health and GreenVision Acquisition, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tivity Health12502.50
GreenVision Acquisition0000N/A

Tivity Health currently has a consensus price target of $22.1250, indicating a potential downside of 5.33%. Given Tivity Health's higher probable upside, research analysts clearly believe Tivity Health is more favorable than GreenVision Acquisition.

Earnings & Valuation

This table compares Tivity Health and GreenVision Acquisition's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tivity Health$1.13 billion1.02$-286,820,000.00$2.0211.57
GreenVision AcquisitionN/AN/AN/AN/AN/A

GreenVision Acquisition has lower revenue, but higher earnings than Tivity Health.

Institutional & Insider Ownership

91.6% of Tivity Health shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. 11.8% of Tivity Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Tivity Health beats GreenVision Acquisition on 7 of the 8 factors compared between the two stocks.

SOC Telemed (NASDAQ:TLMD) and GreenVision Acquisition (NASDAQ:GRNV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares SOC Telemed and GreenVision Acquisition's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SOC TelemedN/AN/AN/A
GreenVision AcquisitionN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for SOC Telemed and GreenVision Acquisition, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SOC Telemed01502.83
GreenVision Acquisition0000N/A

SOC Telemed currently has a consensus price target of $11.40, indicating a potential upside of 67.89%. Given SOC Telemed's higher probable upside, research analysts clearly believe SOC Telemed is more favorable than GreenVision Acquisition.

Earnings & Valuation

This table compares SOC Telemed and GreenVision Acquisition's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOC TelemedN/AN/A$20,000.00N/AN/A
GreenVision AcquisitionN/AN/AN/AN/AN/A

Institutional & Insider Ownership

20.7% of SOC Telemed shares are owned by institutional investors. Comparatively, 67.7% of GreenVision Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

SOC Telemed beats GreenVision Acquisition on 2 of the 3 factors compared between the two stocks.


GreenVision Acquisition Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.7$37.68flat$22.07 billion$19.58 billion14.95
DaVita logo
DVA
DaVita
1.7$108.23flat$11.84 billion$11.39 billion16.23
Sotera Health logo
SHC
Sotera Health
2.0$25.93flat$7.34 billionN/A0.00Analyst Upgrade
Progyny logo
PGNY
Progyny
1.5$49.85flat$4.35 billion$229.68 million453.18
Tivity Health logo
TVTY
Tivity Health
1.0$23.37flat$1.15 billion$1.13 billion-2.11News Coverage
SOC Telemed logo
TLMD
SOC Telemed
1.6$6.79flat$608.55 millionN/A0.00
Ontrak logo
OTRK
Ontrak
1.7$31.29flat$553.52 million$35.10 million-18.41
Viemed Healthcare logo
VMD
Viemed Healthcare
1.1$9.75flat$382.05 million$80.26 million13.54News Coverage
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.61flat$95.79 millionN/A-2.52Decrease in Short Interest
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.13flat$79.26 millionN/A-0.32Increase in Short Interest
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.